Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Encysive Pharmaceuticals has commercially launched Thelin 100mg tablets in Italy for the treatment of pulmonary arterial hypertension.
Subscribe to our email newsletter
Encysive received European Union marketing authorization for Thelin from the European Commission in August 2006. The European Commission’s centralized licensing procedure permits Encysive to market Thelin in all 27 member states of the EU.
Thelin has already been launched in UK, Germany, Ireland, Spain, France and the Netherlands and will be launched in additional EU member states as local government approval for reimbursement is obtained.
Thelin is indicated for improving exercise capacity in pulmonary arterial hypertension (PAH) patients classified as World Health Organization functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease (CTD).
Thelin is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with PAH.
George Cole, president and CEO of Encysive, said: “The launch of Thelin in Italy marks an important achievement for Encysive Pharmaceuticals. Thelin is now being commercialized in the five largest markets in the EU, positioning us for substantial sales growth in 2008.”